Astex Announces Clinical Trial Authorization for Novel Cancer Drug AT7519 and Plans for Two Further New Drug Filings in the Next Nine Months

CAMBRIDGE, U.K., May 23, 2005 (PRIMEZONE) -- Astex:

 -- Astex announces first CTA for novel cancer drug

 -- AT7519 went from first synthesis to CTA approval in just 14 months 
    -- less than half the industry average

 -- Signifies transition from platform to product company

Full press release attached below:


Contact Data